Prof. Dr. İrfan Çiçin

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

European Urology Open Science, 2022

DOI 10.1016/j.euros.2022.08.018 PMID 36353661 13 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Critical Reviews in Oncology/Hematology, 2022

DOI 10.1016/j.critrevonc.2022.103847 PMID 36257531 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Gastric Cancer, 2022

DOI 10.1007/s10120-021-01271-9 PMID 34997449 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Breast Cancer Targets and Therapy, 2022

DOI 10.2147/bctt.s380754 PMID 36105268 12 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Clinical Genitourinary Cancer, 2022

DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 atıf (Europe PMC) Kaynak: OpenAlex

Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

Journal of Cancer Research and Therapeutics, 2022

DOI 10.4103/jcrt.jcrt_1620_21 PMID 37470607 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Recurrent Delayed Immune-Related Pneumonitis After Immune-Checkpoint Inhibitor Therapy for Advanced Osteosarcoma

Immunotherapy, 2022

DOI 10.2217/imt-2021-0275 PMID 35152716 7 atıf (Europe PMC) Kaynak: OpenAlex

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Future Oncology, 2022

DOI 10.2217/fon-2022-0455 PMID 36040321 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Cancers, 2022

DOI 10.3390/cancers14051168 PMID 35267477 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9016 70 atıf (OpenAlex) Kaynak: OpenAlex

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9041 3 atıf (OpenAlex) Kaynak: OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Research Square, 2022

DOI 10.21203/rs.3.rs-1447957/v1 Açık erişimli tam metinKaynak: OpenAlex

Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series

2022

DOI 10.32388/ub8v1e Açık erişimli tam metinKaynak: OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bursa Uludag University - AVESIS, 2022

Kaynak: OpenAlex

Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide

Actas Urologicas Espanolas, 2022

DOI 10.1016/j.acuro.2021.04.005 PMID 35256324 10 atıf (Scopus) Kaynak: Scopus

Role of Investigator

Clinical Research at Mena Challenges and Solutions, 2022

Kaynak: Scopus

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Journal of Men s Health, 2021

DOI 10.31083/jomh.2021.041 5 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The Lancet, 2021

DOI 10.1016/s0140-6736(21)00228-2 PMID 33581821 644 atıf (Europe PMC) Kaynak: OpenAlex

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

JAMA Oncology, 2021

DOI 10.1001/jamaoncol.2021.3523 PMID 34473194 225 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.20.03579 PMID 33513313 204 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Clinical Lung Cancer, 2021

DOI 10.1016/j.cllc.2021.04.005 PMID 34034991 39 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

British Journal of Cancer, 2021

DOI 10.1038/s41416-021-01532-5 PMID 34621044 27 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma

Supportive Care in Cancer, 2021

DOI 10.1007/s00520-021-06627-6 PMID 34677649 14 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer

Molecular Biology Reports, 2021

DOI 10.1007/s11033-021-06694-2 PMID 34498162 9 atıf (Europe PMC) Kaynak: OpenAlex

Secondary Pneumothorax During Immunotherapy in two Patients with Metastatic Solid Tumors; a New Entity

Immunotherapy, 2021

DOI 10.2217/imt-2020-0233 PMID 33820440 7 atıf (Europe PMC) Kaynak: OpenAlex

Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

Future Oncology, 2021

DOI 10.2217/fon-2021-0717 PMID 34726480 7 atıf (Europe PMC) Kaynak: OpenAlex

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

European Journal of Breast Health, 2021

DOI 10.4274/ejbh.galenos.2021.2021-9-9 PMID 35059593 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

PubMed, 2021

PMID 34761635 5 atıf (Europe PMC) Kaynak: OpenAlex

Prognostic Factors for Survival in Transverse Colon Cancers

Journal of Gastrointestinal Cancer, 2021

DOI 10.1007/s12029-021-00675-1 PMID 34302255 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review

Current Problems in Cancer, 2021

DOI 10.1016/j.currproblcancer.2020.100704 PMID 33446319 1 atıf (Europe PMC) Kaynak: OpenAlex

Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival.

PubMed, 2021

PMID 34268945 2 atıf (Europe PMC) Kaynak: OpenAlex

Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma

Tumori Journal, 2021

DOI 10.1177/0300891621996448 PMID 33624577 2 atıf (Europe PMC) Kaynak: OpenAlex

Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.

PubMed, 2021

PMID 34565028 2 atıf (Europe PMC) Kaynak: OpenAlex

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9085 9 atıf (OpenAlex) Kaynak: OpenAlex

Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

Cancer Research, 2021

DOI 10.1158/1538-7445.am2021-ct179 10 atıf (OpenAlex) Kaynak: OpenAlex

Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9038 3 atıf (OpenAlex) Kaynak: OpenAlex

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.9078 3 atıf (OpenAlex) Kaynak: OpenAlex

Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.6_suppl.321 1 atıf (OpenAlex) Kaynak: OpenAlex

Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Cancer Research, 2021

DOI 10.1158/1538-7445.sabcs20-ot-09-09 Kaynak: OpenAlex

Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

Kaynak: OpenAlex

Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

Journal of Clinical Oncology, 2021

DOI 10.1200/jco.2021.39.15_suppl.e15561 Kaynak: OpenAlex

The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.

PubMed, 2021

PMID 34268970 Kaynak: OpenAlex

Distribution Data of Epidermal Growth Factor Receptor Mutations Detected by Next-Generation Sequencing Method in Non-Small Cell Lung Cancer

Journal of Oncological Sciences, 2021

DOI 10.37047/jos.2021-84407 Açık erişimli tam metinKaynak: OpenAlex

Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

Bursa Uludag University - AVESIS, 2021

Kaynak: OpenAlex

AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Trakya University's Institutional Open Access System (Trakya University), 2021

Kaynak: OpenAlex

Merkel cell carcinoma in Turkey: A multicentric study

Journal of Cancer Research and Therapeutics, 2021

DOI 10.4103/jcrt.jcrt_950_19 PMID 34916389 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Need for patient education and better physician-patient communication in melanoma patients: Behaviors and knowledge of melanoma patients

TURKDERM, 2021

DOI 10.4274/turkderm.galenos.2020.44538 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Health Economics Review, 2021

DOI 10.1186/s13561-021-00322-2 PMID 34173876 26 atıf (Scopus) Açık erişimli tam metinKaynak: Scopus

Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study

Journal of B U on, 2021

Kaynak: Scopus

Investigation of the relationship of TNFRSF11A gene polymorphisms with breast cancer development and metastasis risk in patients with BRCA1 or BRCA2 pathogenic variants living in the Trakya region of Turkey

Balkan Journal of Medical Genetics, 2021

DOI 10.2478/bjmg-2020-0016 PMID 33816072 2 atıf (Scopus) Açık erişimli tam metinKaynak: Scopus